Russia Registers a New Drug to Treat COVID-19: ILSIRA

News784

(TELESUR) – It helps to avoid the cytokine storm that the new coronavirus causes in severe cases.

Russia’s Health Ministry Saturday reported that the biotech company BIOCAD has registered a second local drug to treat COVID-19.

The new preparation Levilimab, which will be marketed under the name ILSIRA, is an inhibitor of the interleukin-6 glycoprotein and allows it to contain the body’s immune response and avoid the cytokine storm that the new coronavirus causes in severe cases.

“The drug is recommended to treat seriously ill patients, when the so-called cytokine storm develops, the exaggerated inflammation due to the coronavirus that damages tissues and organs, particularly lung tissue,” the Health Ministry stated.

Initially developed to treat rheumatic arthritis, the ILSIRA was registered through a rapid procedure, which is a procedure contemplated for emergencies.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.